3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
9
Triple Negative Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Neoplasms
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
2
enfortumab vedotin
2
Gemcitabine
2
Carboplatin
2
zimberelimab
1
sirtratumab vedotin
1
sacituzumab govitecan
1
olaparib
1
avelumab
1
Oxaliplatin
1
Nivolumab
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Urothelial Cancer
×
sacituzumab govitecan
×
Genitourinary
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA